Amphastar Pharmaceuticals, Inc.
AMPHHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, Amphastar Pharmaceuticals, Inc. (AMPH) is listed under Drug Manufacturers - Specialty & Generic. Valued at $870.6M, AMPH is a small-cap name in its sector. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.
Market Cap
$870.6M
Beta
0.89
P/E (TTM)
11.97
P/E (Fwd)
6.50
EPS (TTM)
$1.65
EPS (Fwd)
$3.04
ROE
10.4%
ROA
5.3%
Cash
$292.0M
Total Debt
$686.4M
Free CF
$103.1M
52W Change
-4.2%
Annual Financials
Cash vs Debt
Amphastar Pharmaceuticals, Inc. carries $686.4M in total debt against $292.0M in cash reserves — debt is roughly 2.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $103.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 10.4% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $499.0M (2022) to $719.9M (2025), reflecting a 44% increase over the period.
Investors considering Amphastar Pharmaceuticals, Inc. should weigh the typical risks associated with AMPH's sector, size, and financial profile against their own risk tolerance and investment objectives. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Amphastar Pharmaceuticals, Inc. and its sector.